ArticleCureus2026
Mild Encephalopathy With a Reversible Splenial Lesion Type II in a Probable Post-infectious SARS-CoV-2 Context: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild encephalopathy with a reversible splenial lesion (MERS) is a clinico-radiological syndrome characterized by acute encephalopathy and a transient lesion in the splenium of the corpus callosum on magnetic resonance imaging (MRI). We report a case of a six-year-old girl who presented with behavioral disturbance and altered mental status after one week of a viral prodrome in the setting of household SARS-CoV-2 exposure. Cerebrospinal fluid analysis was unremarkable, and SARS-CoV-2 serology showed positive immunoglobulin G (IgG) and negative immunoglobulin M (IgM). Brain MRI demonstrated a focal splenial lesion with bilateral cerebellar involvement of the dentate nuclei, consistent with MERS type II. The patient initially received ceftriaxone and acyclovir for suspected encephalitis. Neurological deterioration with dysphagia led to treatment with intravenous methylprednisolone followed by intravenous immunoglobulin. Follow-up MRI at one month showed complete lesion resolution, and complete neurological recovery was achieved by three months. This case highlights the importance of recognizing this reversible clinico-radiological pattern in children with acute encephalopathy to facilitate diagnosis, guide management, and avoid unnecessary investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.